Stocktoria
PHIBRO ANIMAL HEALTH CORP PAHC
PHIBRO ANIMAL HEALTH CORP financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $1.0B | $977.9M | $942.3M | $833.4M | $800.4M | $828.0M | $820.0M | $764.3M |
| Gross profit | $512.5M | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M | $256.9M | $264.6M | $266.9M | $248.2M |
| R&D expense | $24.6M | $23.7M | $29.2M | $24.4M | $20.8M | $17.8M | $13.7M | $12.1M | $10.0M | $9.4M |
| SG&A expense | $318.1M | $289.5M | $259.8M | $226.4M | $206.4M | $196.5M | $187.7M | $181.4M | $168.0M | $150.3M |
| Operating income | $194.4M | $110.5M | $53.3M | $71.8M | $79.0M | $74.9M | $69.2M | $83.2M | $98.9M | $97.9M |
| Interest expense | — | — | — | $18.7M | $12.7M | $13.7M | $14.6M | $13.7M | $13.6M | — |
| Income tax | $37.6M | $19.7M | $8.5M | $21.5M | $23.2M | $12.1M | $22.0M | $16.8M | $23.2M | $15.9M |
| Net income | $99.7M | $48.3M | $2.4M | $32.6M | $49.2M | $54.4M | $33.6M | $54.7M | $64.9M | $64.6M |
| EPS (diluted) | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.61 |
| Operating cash flow | $69.0M | $80.1M | $87.6M | $13.3M | $31.6M | $48.3M | $59.3M | $47.2M | $70.0M | $98.4M |
| Cash & equivalents | $61.4M | $68.0M | $70.6M | $41.3M | $74.2M | $50.2M | $36.3M | $57.6M | $29.2M | $56.1M |
| Inventory | $534.9M | $444.4M | $265.9M | $277.6M | $259.2M | $216.3M | $196.7M | $198.3M | $178.2M | $161.2M |
| Total assets | $1.5B | $1.4B | $982.2M | $971.4M | $931.7M | $841.3M | $784.1M | $726.7M | $671.7M | $623.4M |
| Total liabilities | $1.1B | $1.1B | $725.5M | $688.9M | $669.3M | $602.8M | $595.9M | $510.7M | $486.7M | $472.2M |
| Shareholders' equity | $385.5M | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M | $188.2M | $216.0M | $185.0M | $151.2M |
Growth · year-over-year · Revenue CAGR 7.9%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +17.1% | +27.4% | +4.1% | +3.8% | +13.1% | +4.1% | -3.3% | +1.0% | +7.3% | +1.7% |
| Net income growth | +106.6% | +1897.7% | -92.6% | -33.7% | -9.6% | +62.1% | -38.7% | -15.7% | +0.4% | -21.9% |
| EPS growth | +104.2% | +1883.3% | -92.6% | -33.1% | -9.7% | +61.4% | -38.5% | -16.1% | +0.0% | -22.2% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-06-30. Facts plus Stocktoria's own computed scores — not investment advice.